Skip to main content
SpringerLink
Log in

PET/CT with [18F]FDG in Cervical Cancer

  • Chapter
  • First Online:
Imaging in Clinical Oncology

  • 2750 Accesses

Abstract

Positron emission tomography/computed tomography (PET/CT) with the use of glucose analogue 2-[18F]fluoro-2-deoxy-d-glucose, [18F]FDG, has a major impact in oncology. Nowadays there is a growing body of evidence supporting the use of [18F]FDG-PET/CT in gynaecological malignancies. Concerning the cervical cancer, imaging with [18F]FDG-PET/CT is not routinely used for the initial diagnosis but the preoperative [18F]FDG uptake in the primary tumour seems to offer significant prognostic information. Also, [18F]FDG-PET/CT is an important tool for initial staging particularly in identifying involved lymph nodes and distant metastasis while it may impact external-beam radiotherapy planning. Finally, it is reported as an important diagnostic tool for detecting recurrent cervical cancer in clinically equivocal patients and for monitoring posttreatment metabolic response. Concerning the ovarian cancer, [18F]FDG-PET/CT is not used for initial diagnosis because of false positive results but it may contribute to the detection of metastases outside the pelvis in the initial staging. There are published data for the value of [18F]FDG-PET/CT in radiotherapy planning and accurate restaging after treatment, but this method seems to have the greatest utility in ovarian cancer recurrence detection, mainly in patients with an increase of the tumour marker CA-125 and negative or inconclusive findings at CT or MRI. Finally, for the endometrial cancer there are few studies that support that [18F]FDG-PET/CT may play role as a prognostic factor and offer a high accuracy in the evaluation of recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chung HH, Nam BH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, Kang SB (2010) Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. Eur J Nucl Med Mol Imaging 37:1467–1473

    Article  PubMed  Google Scholar 

  2. Haie-Meder C, Mazeron R, Magne N (2010) Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers. Radiother Oncol 96:351–355

    Article  PubMed  Google Scholar 

  3. Petsuksiri J, Jaishuen A, Pattaranutaporn P, Chansilpa Y (2012) Advanced imaging applications for locally advanced cervical cancer. Asian Pac J Cancer Prev 13:1713–1718

    Article  PubMed  Google Scholar 

  4. Yoon MS, Ahn SJ, Nah BS, Chung WK, Song HC, Yoo SW, Song JY, Jeong JU, Nam TK (2012) Metabolic response of lymph nodes immediately after RT is related with survival outcome of patients with pelvic node-positive cervical cancer using consecutive [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography. Int J Radiat Oncol Biol Phys 84:e491–e497

    Article  PubMed  Google Scholar 

  5. Lin WC, Hung YC, Yeh LS, Kao CH, Yen RF, Shen YY (2003) Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol 89:73–76

    Article  PubMed  Google Scholar 

  6. Yeh LS, Hung YC, Shen YY, Kao CH, Lin CC, Lee CC (2002) Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings. Oncol Rep 9:1289–1292

    PubMed  Google Scholar 

  7. Grigsby PW (2005) 4th international cervical cancer conference: update on PET and cervical cancer. Gynecol Oncol 99(3 suppl 1):S173–S175

    Article  PubMed  Google Scholar 

  8. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL (1999) Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 40:1125–1131

    PubMed  CAS  Google Scholar 

  9. Choi HJ, Roh JW, Seo SS et al (2006) Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer 106:914–922

    Article  PubMed  Google Scholar 

  10. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER (2005) FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 97:183–191

    Article  PubMed  Google Scholar 

  11. Kim SK, Choi HJ, Park SY et al (2009) Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. Eur J Cancer 45:2103–2109

    Article  PubMed  Google Scholar 

  12. Choi HJ, Ju W, Myung SK, Kim Y (2010) Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci 101:1471–1479

    Article  PubMed  CAS  Google Scholar 

  13. Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, Nedergaard L, Højgaard L, Engelholm SA (2007) The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 106:29–34

    Article  PubMed  Google Scholar 

  14. Yildirim Y, Sehirali S, Avci ME, Yilmaz C, Ertopcu K, Tinar S, Duman Y, Sayhan S (2008) Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings. Gynecol Oncol 108:154–159

    Article  PubMed  CAS  Google Scholar 

  15. American College of Radiology (2010) ACR appropriateness criteria. Women’s imaging: staging of invasive cancer of the cervix. http://www.acr.org/. Accessed 20 Mar 2010

  16. Kizer NT, Zighelboim I, Case AS, Dewdney SB, Thaker PH, Massad LS (2009) The role of PET/CT in the management of patients with cervical cancer: practice patterns of the members of the society of gynecologic oncologists. Gynecol Oncol 114:310–314

    Article  PubMed  Google Scholar 

  17. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF (2004) To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 45(suppl 1):56S–65S

    PubMed  CAS  Google Scholar 

  18. van der Veldt AA, Buist MR, van Baal MW, Comans EF, Hoekstra OS, Molthoff CF (2008) Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET. J Nucl Med 49:1936–1943

    Article  PubMed  Google Scholar 

  19. Chung HH, Jo H, Kang WJ et al (2007) Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 104:529–534

    Article  PubMed  Google Scholar 

  20. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Sugimura K (2008) Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol 18:2040–2047

    Article  PubMed  Google Scholar 

  21. Sironi S, Picchio M, Landoni C, Galimberti S, Signorelli M, Bettinardi V et al (2007) Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging 34:472–479

    Article  PubMed  Google Scholar 

  22. Mittra E, El-Maghraby T, Rodriguez CA, Quon A, McDougall IR, Gambhir SS, Iagaru A (2009) Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 36:1952–1959

    Article  PubMed  CAS  Google Scholar 

  23. Jover R, Lourido D, Gonzalez C, Rojo A, Gorospe L, Alfonso JM (2008) Role of PET/CT in the evaluation of cervical cancer. Gynecol Oncol 110(3 suppl 2):S55–S59

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, Evangelismos General Hospital, Ipsilantou 45–47, 10676, Athens, Greece

    Evangelia V. Skoura & Ioannis E. Datseris

Authors
  1. Evangelia V. Skoura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ioannis E. Datseris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ioannis E. Datseris .

Editor information

Editors and Affiliations

  1. University of Athens, Greece, Athens, Greece

    Athanasios D. Gouliamos

  2. Hygeia and Mitera Hospital, Athens, Greece

    John Andreou

  3. Hygeia Hospital, Athens, Greece

    Paris Kosmidis

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Skoura, E.V., Datseris, I.E. (2014). PET/CT with [18F]FDG in Cervical Cancer. In: Gouliamos, A., Andreou, J., Kosmidis, P. (eds) Imaging in Clinical Oncology. Springer, Milano. https://doi.org/10.1007/978-88-470-5385-4_40

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5385-4_40

  • Published:

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5384-7

  • Online ISBN: 978-88-470-5385-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation